Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PJ017
- Development stage
- Preclinical
- Lead developer
- Chongqing Peg-Bio Biopharm
- Modality
- Recombinant Proteins and Enzymes
01
Overview
PJ017 is a preclinical-stage PEGylated recombinant L-asparaginase mutant being developed by Chongqing Peg-Bio Biopharm for the treatment of solid tumors (malignant tumors other than leukemia). Designed using computer simulation to obtain an innovative asparaginase mutant, the enzyme is subsequently modified via site-specific PEGylation to improve its pharmacokinetic profile and reduce immunogenicity. PJ017 acts by depleting circulating L-asparagine, an essential amino acid that certain tumor cells cannot synthesize endogenously, thereby starving the tumor cells and inhibiting their growth.
- Other names
- PEGylated L-asparaginase mutantPEGylated asparaginase mutant
Beyond the preview
Go deeper on PJ017.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PJ017.